Investigations on the Nature of Hemophilia A^[*]

Summary

In this paper an inhibitor is described that is found in hemophilic plasma and serum different from any till now described inhibitor. The inhibitor only inhibits prothrombin activation in the “intrinsic clotting systems”. This inhibitor is probably not present in normal human plasma or serum. It is destroyed by ether and freeze drying, is labile to acid and storage at room temperature. It is stable upon dialysis and has not been adsorbed on barium sulfate, aluminum hydroxide or kaolin. It precipitates at 50% v/v saturation with alcohol. The nature of this inhibitor seems to be a protein or lipoprotein.

Factor VIII was isolated from hemophilic plasma. The amount isolated was the same as from normal plasma and the activity properties were not different. Hemophiliacs have normal amounts of factor VIII.

^* This investigation was supported by a research grant from the Deutsche Forschungsgemeinschaft.

^** Present address: Department of Physiology and Pharmacology, Wayne State University, College of Medicine, Detroit, Michigan, USA.

• References

• 1 Baker W. R, Seegers W. H. Some Properties of Platelet Cofactor I Concentrates of Bovine Origin. Thrombos. Diathes. haemorrh 04: 342 1960;
• 2 Bergna L. J, Pavlovsky A. Classification of Hemophiliacs with Development of Anticoagulant. Acta haemat 16: 247 1956;
• 3 Biggs R. The Inhibitory Effect of Hemophilic Plasma. Brit. J. Haemat 04: 192 1958;
• 4 Biggs R. The Treatment of Haemophilic Patients with Animal Antihaemophilic Globulin. Acta haemat 24: 124 1960;
• 5 Biggs R, Douglas A. S. The Thromboplastin Generation Test. J. Clin. Path 06: 23 1953;
• 6 Blombck M, Nilsson I. M. Treatment of Hemophilia-A with Human Antihemophilic Globulin. Acta Med. Scand 161: 301 1958;
• 7 Brinkhous K. M. A Study of the Clotting Defect in Hemophilia: The Delayed Formation of Thrombin. Am. J. Med. Sci 198: 509 1939;
• 8 Brinkhous K. M. Physiopathology of Hemophilia. Acta haemat 20: 125 1958;
• 9 Conley C. L, Hartmann R. C. A Hemorrhagic Disorder Caused by Circulating Anticoagulant in Patients with Disseminated Lupus Erythematodes. J. Clin. Invest 31: 621 1952;
• 10 Conley C. L, Rathburn H. K, Morse W. I, Robinson J. E. Circulating Anticoagulant as a Cause of Hemorrhagic Diathesis in Man. Bull. Johns Hopkins Hosp 83: 288 1948;
• 11 Deutsch E. Hemmkörperhämophilie. Springer; Wien: 1950
• 12 Deutsch E. Über eine eigentümliche hämorrhagische Diathese: Die Hemmkörperhämophilie. Klin. Wschr 28: 326 1950;
• 13 Deutsch E. Die hämophilie-ähnlichen hämorrhagischen Diathesen. Ergebn. inn. Med. Kinderheilk 05: 553 1954;
• 14 Deutsch E. Die Immunkoagulopathien. Mod. Probl. Paediat 03: 77 1958;
• 15 Deutsch E, Mammen E. The Inactivation of Plasmathromboplastin. Thrombos. Diathes. haemorrh 02: 324 1958;
• 16 Duke W. W. A Simple Instrument for Determining the Coagulation-Time of the Blood. Arch. Int. Med 09: 258 1912;
• 17 Egeberg O, Borchgrevink C. F, Hjort P. F. Use of Animal Anti- haemophilic Globulin in Surgery: Exarticulation in the Hip in a Haemophiliac. Acta Med. Scand 167: 415 1960;
• 18 Egli H, Schneider W. Untersuchungen über den Faktor IX. Thrombos. Diathes. haemorrh 07: 523 1962;
• 19 Feissly R, Lüdin A. Action de la cocaine sur les plaquettes sanguines. Helv. physiol. Acta 07: 9 1949;
• 20 Fischer M, Cancura W, Deutsch E. Die Behandlung einer Hämophilie-A mit antihämophilem Globulin vom Schwein. Wiener klin. Wschr 73: 312 1961;
• 21 Folin O, Ciocalteu V. On Tyrosine and Tryptophane Determinations in Proteins. J. Biol. Chem 73: 627 1927;
• 22 Frommeyer W. B, Epstein R. D, Taylor F. H. L. Refractoriness in Hemophilia to Coagulation-Promoting Agents: Whole Blood and Plasma Derivatives. Blood 05: 401 1950;
• 23 Gasser H. Über Hemmkörperhämophilie bei Pemphigus vulgaris. Dtsch. Arch. klin. Med 203: 617 1957;
• 24 Graham J. B, Barrow E. M. The Pathogenesis of Hemophilia. An Experimental Analysis of the Anticephalin Hypothesis in Hemophilic Dogs. J. exp. Med 106: 273 1957;
• 25 Hall M. Haemophilia Complicated by an Acquired Circulating Anticoagulant. A Report of Three Cases. Brit. J. Haemat 07: 340 1961;
• 26 Hardistry R. M. Acquired Haemophilia-Like Disease. J. Clin. Path 07: 26 1954;
• 27 Harmison C. R, Seegers W. H. Some Physicochemical Properties of Bovine Autoprothrombin II. J. Biol. Chem. in press. 1962
• 28 Hecht E, Shapiro D. Sphingosine as an Inhibitor of Blood Clotting. Science 125: 1041 1957;
• 29 Hitzig W. H, Labhart A, Uehlinger E. Transitorische Hemmkörperhämophilie bei Rheumatismus. Helv. med. Acta 18: 410 1951;
• 30 Hougie C. Pseudo-Haemophilia: An Acquired Hemorrhagic Diathesis Due to a Circulating Anticoagulant. J. Clin. Path 06: 30 1953;
• 31 Hougie C. Circulating Anticoagulants. Brit. Med. Bull 11: 16 1955;
• 32 Hougie C. Pathogenesis of Haemophilia: A Critical Analysis of the Evidence for the Bridge Anticoagulant. Brit. J. Haemat 05: 177 1959;
• 33 Howell W. H. The Condition of the Blood in Hemophilia, Thrombosis and Purpura. Arch. int. Med 13: 76 1914;
• 34 Imdahl H, Egli H, Buscha H. Über die Bedeutung der Cohnschen Plasma-Fraktion I für die operative Behandlung bei der Hämophilie A. Med. Welt 1961; 1821.
• 35 Israels L. G, Foerster J, Zipursky A. A Natural Occurring Inhibitor of the First Stage of Blood Coagulation. Brit. J. Haemat 06: 275 1960;
• 36 Johnson F. J, Mammen E. F, Seegers W. H. Prothrombin Utilization Following Addition of Platelet Cofactor I Concentrates to Hemophilic Plasma. Thrombos, Diathes. haemorrh 03: 588 1959;
• 37 Johnson S. A, McClaughry R. I, Seegers W. H. Nature of the Blood Clotting Mechanisms in Hemophilia. J. Mich. State Med. Soc 54: 797 1955;
• 38 Johnson S. A, Rutzky J, Schneider Ch. L, Seegers W. H. Activation of Purified Prothrombin with Hemophilia Plasma. Proc. 4. Congr. Internat. Soc. Hemat. 1952
• 39 Johnson S. A, Seegers W. H. Use of Purified Prothrombin in the Study of Hemophilia and Plasma Thromboplastin Component (PTC) Deficiency. J. Appl. Physiol 06: 429 1954;
• 40 Johnson S. A, Seegers W. H. Studies on the Plasma Defect in Hemophilia. Rev. Hémat 09: 529 1954;
• 41 Johnson S. A, Seegers W. H. Platelet Cofactor I Activity in the Hemophiliacs. “Hemophilia and Hemophiloid Diseases”. Edit. Brinkhous K. M. Univ. of North Carolina Press; 1957
• 42 Kewick R. A, Wolf P. A Concentrate of Human Antihemophilic Factor. Its Use in Six Cases of Haemophilia. Lancet 01: 647 1957;
• 43 Kowarzyk H, Marciniak E. The Significance of Prothrombin Derivatives. Proc. 8. Congr. Europ. Soc. Hemat., Vienna. 1961
• 44 Kowarzyk H, Marciniak E. Trombogenezza. Polski Tygod. Lekar 16: 1641 1961;
• 45 Larrieu M. J, Soulier J. P. Deficit en fracteur antihémophilique A chez une fille, associé a un trouble du saignement. Rev. hémat 08: 361 1953;
• 46 Lewis J. H, Ferguson J. H. Hemorrhagic Diathesis Due to PTC (Plasma Thromboplastin Component) Deficiency. Proc. Soc. exp. Biol, and Med 82: 445 1953;
• 47 Macfarlane R. G, Biggs R, Bidwell E. Bovine Antihaemophilic Globulin in the Treatment of Haemophilia. Lancet 01: 1316 1954;
• 48 Macfarlane R. G, Mallam P. C, Witts L. J, Bidwell E, Biggs R, Fraenkel G. J, Honey G. E, Taylor K. B. Surgery in Hemophilia: The Use of Animal Antihemophilic Globulin and Human Plasma in Thirteen Cases. Lancet II: 251 1957;
• 49 Mammen E. Isolierung von Plättchencofaktor I (Antihämophiles Globulin), aus Rinderserum. Klin. Wschr 39: 872 1961;
• 50 Mammen E. Der Nachweis von Plättchencofaktor I (Faktor VIII) im Serum und seine Isolierung aus Seren. Proc. 8. Congr. Europ. Soc. Hemat. Vienna. 1961
• 51 Mammen E. F, Thomas W. R, Seegers W. H. Activation of Purified Prothrombin to Autoprothrombin I or Autoprothrombin II (Platelet Cofactor II) or Autoprothrombin IÏ-A. Thrombos. Diathes. haemorrh 05: 218 1960;
• 52 Mammen E. F, Yoshinari M, Seegers W. H. Platelet Cofactors as Plasma Components of the Intrinsic Blood Clotting Mechanisms. Thrombos. Diathes. haemorrh 05: 38 1960;
• 53 Marciniak E. Autoprothrombin Activation in Serum. Bull. Acad. Polon. Sei 09: 381 1961;
• 54 Marciniak E, Seegers W. H. Autoprothrombin C: A Second Enzyme from Prothrombin. Canad. J. Biochem. and Physiol 40: 597 1962;
• 55 Mulder E. Bridge Anticoagulant, a New Entity? Thrombos. Diathes. haemorrh 06: 160 1961;
• 56 Munro F. L. Properties of an Anticoagulant Found in the Blood of a Hemophiliac. J. Clin. Invest 25: 422 1946;
• 57 Nour-Eldin F, Wilkinson J. F. Bridge Anticoagulant: A Hitherto Unrecognized Blood Clotting Inhibitor in Hemophilic and Christmas Disease Plasma, A Simple Method for its Demonstration. Brit. J. Haemat 04: 38 1958;
• 58 Nour-Eldin F, Wilkinson J. F. In Vivo Study on the Relation Between Bridge Anticoagulant and Antihaemophilic Globulin. Brit. J. Haemat 04: 292 1958;
• 59 Quick A. J. The Thromboplastin Reagent for the Determination of Prothrombin. Science 92: 112 1940;
• 60 Ramot B, Singer K. An Unusual Circulating Anticoagulant in Systemic Lupus Erythematosus. Acta haemat 16: 158 1956;
• 61 Robinson H. W, Hogden C. G. The Biuret Reaction in the Determination of Serum Proteins. J. Biol. Chem 135: 707 727 1940;
• 62 Schullze H. E, Schwick G. Die klinische Bedeutung der differenzierten Bestimmung von Prothrombin und Acceleratoren der Blutgerinnung. Medizinische 1953; 1354: 1386.
• 63 Schwick G. Beiträge zur Diagnostik von Gerinnungsfaktoren. Laboratoriumsblätter für medizinische Diagnostik 01: 46 1961;
• 64 Seegers W. H. The Purification of Prothrombin. Rec. Chem. Progress 13: 143 1952;
• 65 Seegers W. H. A Theoretical Consideration of the Blood Clotting Mechanisms in Hemophilia. Schweiz. Med. Wschr 84: 1 1954;
• 66 Seegers W. H. Prothrombin. Harvard University Press; Cambridge, Mass: 1962
• 67 Seegers W. H, Loomis E. C, Vandenbelt J. M. Preparation of Prothrombin Products: Isolation of Prothrombin and its Properties. Arch. Biochem 06: 85 1945;
• 68 Seegers W. H, Mammen E, Lee J. M, Landaburu R. H, Cho M. H, Baker W. J, Shepard R. S. Further Studies on the Purification of Platelet Cofactor I. “Hemophilia and Other Hemorrhagic States”. Edit. Brinkhous K. M. Univ. of North Carolina Press; 1959
• 69 Seegers W. H, Marciniak E. Autoprothrombin C in Irregular Blood Clotting. Thrombos. Diathes. haemorrh 08: 1 1962;
• 70 Seegers W. H, Smith H. P. Factors which Influence the Activity of Purified Thrombin. Am. J. Physiol 137: 348 1942;
• 71 Serafini U. M. The Significance of the Socalled “Bridge Anticoagulant”. “Hemophilia and Other Hemorrhagic States”. Edit. Brinkhous K. M. Univ. of North Carolina Press; 1959
• 72 Shanberge J. N, Gore I. Studies on the Immunologic and Physiologic Activities of Antihemophilic Factor (AHF). J. Lab. Clin. Med 50: 954 1957;
• 73 Singer K, Mond E, Hyman J, Levy R. C. Circulating Anticoagulants in Hemophilia and in Hemophilia-Like Diseases. Blood 05: 1135 1950;
• 74 Spaet T. h. H, Garner E. S. Inactivation of Thromboplastin in Human Blood. J. Clin. Invest 34: 1807 1955;
• 75 Spaet T. h. H, Garner E. S. Studies on the Storage Lability of Human Anti-haemophilic Factor. J. Lab. Clin. Med 46: 111 1955;
• 76 Speer R. J, Hill J. M, Maloney M, Roberts A, Prager M. D. An Unusual Coagulation Inhibitor Encountered in Refractory Hemophilia. Am. J. Clin. Path 26: 477 1956;
• 77 Tocantins L. M. Antithromboplastic Activity of Normal and Hemophilic Plasmas. Fed. Proc 01: 85 1942;
• 78 Tocantins L. M. Demonstration of Antithromboplastic Activity in Normal and Hemophilic Plasmas. Am. J. Physiol 139: 265 1943;
• 79 Tocantins L. M. Cephalin, Protamine and the Antithromboplastic Activity of Normal and Hemophilic Plasmas. Proc. Soc. exp. Biol, and Med 54: 94 1943;
• 80 Tocantins L. M. Anticephalin Activity and the Prothrombin Conversion Rate of Normal and Hemophilic Plasmas. Proc. Soc. exp. Biol, and Med 55: 291 1944;
• 81 Tocantins L. M. Hemophilic Syndromes and Hemophilia. Blood 09: 281 1954;
• 82 Tocantins L. M. Discussion to Inhibitors in Hemophilia. “Progress in Coagulation”. Schattauer, Stuttgart, 1962: 100.
• 83 Tocantins L. M, Carroll R. T. Coagulation Decelerating Action of Hemophilic Plasma on Normal Plasma. Fed. Proc 08: 157 1949;
• 84 Tocantins L. M, Carroll R. T, Holburn R. R. Clot Accelerating Effect of Dilution on Blood and Plasma. Relation to the Mechanism of Coagulation of Normal and Hemophilic Blood. Blood 06: 720 1951;
• 85 Ulutin O. N, Seegers W. H. Antithrombin II Anticoagulant (Autoprothrombin II-A). Thrombos. Diathes. haemorrh 06: 270 1961;
• 86 Ware A. G, Seegers W. H. Two-Stage Procedure for the Quantitative Determination of Prothrombin Concentrations. Am. J. Clin. Path 19: 471 1949;
• 87 Windörfer A, Schultze H. E, Schwick G. Immuno-Hemmkörper- hämophilie-A. Blut 02: 217 1956;
• 88 Zbinden T, Leupold R. Über Hemmkörperhämophilie. Schweiz. Med. Wschr 87: 1478 1957;